Murchinson Ltd. Acquires Shares of 62,500 Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Murchinson Ltd. purchased a new stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 62,500 shares of the company’s stock, valued at approximately $152,000. Murchinson Ltd. owned about 0.14% of Werewolf Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of HOWL. PFM Health Sciences LP boosted its position in Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after buying an additional 909,895 shares during the last quarter. Janus Henderson Group PLC bought a new position in Werewolf Therapeutics in the first quarter valued at about $10,922,000. Vanguard Group Inc. boosted its holdings in Werewolf Therapeutics by 26.8% in the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after acquiring an additional 233,909 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Werewolf Therapeutics by 22.8% during the 2nd quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock worth $516,000 after buying an additional 39,413 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Werewolf Therapeutics by 103.1% during the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after buying an additional 86,800 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Trading Down 4.1 %

HOWL opened at $2.10 on Tuesday. The firm’s fifty day moving average is $2.27 and its two-hundred day moving average is $3.87. The firm has a market cap of $91.26 million, a PE ratio of -1.93 and a beta of 0.46. Werewolf Therapeutics, Inc. has a twelve month low of $1.57 and a twelve month high of $8.19. The company has a debt-to-equity ratio of 0.24, a quick ratio of 12.13 and a current ratio of 12.13.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $2.00 million. Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. Equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd. Wedbush reaffirmed an “outperform” rating and set a $9.00 price objective on shares of Werewolf Therapeutics in a research note on Monday, June 3rd. Finally, JMP Securities reissued a “market outperform” rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a research note on Wednesday, June 26th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.